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Abstract
Objective
To determine whether lipids and apolipoproteins predict prognosis of patients with amyo-
trophic lateral sclerosis in a cohort study of 99 patients with amyotrophic lateral sclerosis who
were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology
Clinic in Karolinska University Hospital in Stockholm, Sweden.
Methods
Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol,
triglycerides, apolipoprotein AI, apolipoprotein B, and lipid ratios were measured at the time of
amyotrophic lateral sclerosis diagnosis or shortly thereafter. Death after amyotrophic lateral
sclerosis diagnosis was used as the main outcome. The Cox model was used to estimate hazard
ratios with 95% confidence intervals of death after amyotrophic lateral sclerosis diagnosis, after
controlling for sex, age at diagnosis, site of symptom onset, diagnostic delay, body mass index,
Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised score, and progression rate.
Results
A 1-SD increase of total cholesterol (hazard ratio 0.60, 95% confidence interval 0.41–0.89, p =
0.01), low-density lipoprotein cholesterol (hazard ratio 0.64, 95% confidence interval
0.44–0.92, p = 0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol
ratio (hazard ratio 0.65, 95% confidence interval 0.46–0.92, p = 0.02), apolipoprotein B (hazard
ratio 0.62, 95% confidence interval 0.44–0.88, p = 0.01), or apolipoprotein B/apolipoprotein AI
ratio (hazard ratio 0.61, 95% confidence interval 0.43–0.86, p < 0.01) was associated with
a lower risk of death after amyotrophic lateral sclerosis diagnosis. A dose-response relationship
was also noted when these biomarkers were analyzed as categorical variables.
Conclusions
Lipids and apolipoproteins are important prognostic indicators for amyotrophic lateral sclerosis
and should be monitored at the diagnosis of amyotrophic lateral sclerosis.
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Amyotrophic lateral sclerosis (ALS) is nowadays increasingly
recognized as a systemic disease affecting not only the CNS
but also the whole-body physiology.1 Various hypotheses
have been proposed concerning the potential contributions to
its etiology from outside of the nervous system.2 Specifically,
a growing body of evidence has shown dysregulated energy
metabolism in ALS, which is both clinically distinct and tar-
getable for therapeutic interventions.3
Increased levels of total cholesterol (TC), low-density lipo-
protein cholesterol (LDL-C), triglycerides (TG), and LDL-C/
high-density lipoprotein cholesterol (HDL-C) ratio have been
shown to be more prevalent in patients with ALS than in
controls, although results are not always consistent.4 In a pre-
vious study, we found that compared to controls, patients with
ALS had higher levels of LDL-C, LDL-C/HDL-C, apolipo-
protein (Apo) B, and ApoB/ApoAI ratio already during the 20
years before diagnosis.4 Using results of genome-wide associa-
tion studies (GWAS) on blood lipids and ALS, in a mendelian
randomization analysis, we also demonstrated evidence for
a causal relationship between dyslipidemia and ALS.5 A causal
relationship is also suggested by another 2 recent mendelian
randomization analyses,6,7 although the inclusion of prevalent
patients in the GWAS of ALS and its resultant survival bias
remain a concern for these results.8 The potential role of lipids
on ALS prognosis has also been studied, however with largely
conflicting results.9–22 We summarize findings of the existing
studies in table 1. No study has, on the other hand, examined the
association of ApoB or ApoAI with ALS prognosis, however.
To this end, we constructed a cohort study of 99 patients with
ALS in Stockholm, Sweden, and correlated different lipids and
apolipoproteins with the risk of death after ALS diagnosis,
taking into account other known prognostic indicators of
ALS, namely sex, age at diagnosis, site of symptom onset,
diagnostic delay, body mass index (BMI), Amyotrophic Lat-
eral Sclerosis Functional Rating Scale–Revised (ALSFRS-R)
score, and progression rate.
Methods
Study design
We enrolled 99 patients with ALS (including 2 patients with
progressive spinal muscular atrophy [PSMA]), diagnosed
from September 2015 to October 2018 at the Neurology
Clinic in Karolinska University Hospital in Stockholm, Swe-
den, for the present study. All patients were individually fol-
lowed up from the date of diagnosis until death or October 31,
2018, whichever came first, through the Swedish Motor
Neuron Disease Registry.23
We measured TC (millimoles per liter), LDL-C (millimoles
per liter), HDL-C (millimoles per liter), LDL-C/HDL-C ra-
tio, TG (millimoles per liter), ApoAI (grams per liter), ApoB
(grams per liter), and ApoB/ApoAI ratio of the enrolled
patients using blood samples collected after overnight fasting.
The laboratory tests were conducted on fresh blood samples
by the Laboratory of Karolinska University Hospital. These
measurements were performed at the time of diagnosis or
shortly thereafter. The mean time interval between diagnosis
and lipid and apolipoprotein measurements was 1.12 months,
and 87 of the patients (87.88%) had their measurements
within 2 months after diagnosis.
In addition to vital status (date of death), we obtained in-
formation on sex, date of birth, age at symptom onset, site of
symptom onset, age at diagnosis, BMI at diagnosis, and
ALSFRS-R score at diagnosis from the Swedish Motor Neu-
ron Disease Registry. We calculated diagnostic delay as the
time interval between the time of symptom onset and date of
diagnosis (in months) and progression rate as (48 − ALSFRS-
R score at diagnosis)/diagnostic delay. In addition to the
known prognostic indicators for ALS, we collected in-
formation on standard bicarbonate, which was measured at
the same time as lipids and apolipoproteins, to assess whether
the associations of lipids and apolipoproteins with ALS sur-
vival could be attributable to altered respiratory function.
Overall survival time was calculated as the time interval be-
tween the date of diagnosis and date of death for deceased
patients or the end of the study for the patients who were still
alive at the end of 2018.
To assess the representativeness of the study sample, we
compared the main clinical characteristics between the en-
rolled 99 patients and the remaining 118 patients who were
diagnosed with ALS or PSMA during 2015 to 2018 in
Stockholm according to the Swedish Motor Neuron Disease
Registry but had no measurements on lipids and apolipo-
proteins. No clear difference was noted between these 2
groups in terms of sex, age at diagnosis, site of symptom onset,
diagnostic delay, ALSFRS-R score, and progression rate (data
available from Dryad, supplementary table 1, doi.org/10.
5061/dryad.df02h35). Although patients included in the
present study appeared to have a slightly higher BMI and
mortality rate compared to patients not included, the differ-
ence was only statistically significant for BMI.
Glossary
ALS = amyotrophic lateral sclerosis; ALSFR-R = Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised; Apo =
apolipoprotein; BMI = body mass index; GWAS = genome-wide association studies; HDL-C = high-density lipoprotein
cholesterol; LDL-C = low-density lipoprotein cholesterol; PSMA = progressive spinal muscular atrophy;TC = total cholesterol;
TG = triglycerides.
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Statistical analyses
We first described the characteristics, either as categorical or
continuous variables, of the enrolled patients. Associations of
lipids and apolipoproteins with the risk of death after diagnosis
were assessed by hazard ratios and their 95% confidence inter-
vals (CIs) using Cox proportional hazard regression models. In
these models, we adjusted for sex (men vs women), age at
diagnosis (continuous variable), site of symptom onset (bulbar
vs nonbulbar), diagnostic delay (continuous variable, in
months), BMI at diagnosis (continuous variable), ALSFRS-R
score at diagnosis, and progression rate. Time since diagnosis
was used as the underlying time scale. Because not all patients
Table 1 Summary of previous studies on blood biomarkers of lipid metabolism and ALS prognosis
Article Setting
Sample
size, n Main findings
Reference 9 Patients with ALS, France 369 Low LDL-C/HDL-C ratio (≤2.99) was associated with 35% increased
risk of death.
Reference 10 Patients with ALS consecutively enrolled during
2000–2006 in 2 ALS centers, Italy
658 TC, TG, LDL-C, HDL-C, and LDL-C/HDL-C ratio were not associated
with ALS survival in a multivariate analysis. However, TC, TG, HDL-
C, and LDL-C/HDL-C ratio levels were lower in patients with FVC
<70% compared to patients with FVC ≥90%.
Reference 11 Patients with ALS enrolled through the outpatient clinic
during 1999–2009, Germany
488 LDL-C, HDL-C, and LDL-C/HDL-C ratio were not associated with ALS
survival. However, univariate analysis showed that patients with
TG >1.47 mmol/L and TC >5.23 mmol/L had a longer survival
compared to patients with TG <1.47mmol/L and TC <5.23mmol/L.
Reference 12 Patients with ALS enrolled at University Medical Centre
Utrecht during July 2007–July 2009, the Netherlands
334 In univariate analysis, LDL-C/HDL-C ratio was positively associated
with survival. After adjustment for age, sex, and FVC, no difference
was observed. TC and LDL-C were not associated with survival in
either unadjusted or multivariable analysis.
Reference 15 Patients with ALS enrolled in 3 clinical trial databases 427 After adjustment for BMI, FVC, and age, the LDL-C/HDL-C ratio was
not associated with survival.
Reference 16 Patients with ALS in Japan 92 LDL-C and TC levels measured at diagnosis were inversely
associatedwith the speed of decline in ALSFR-R score and FVC after
diagnosis.
Reference 17 Patients with ALS residing in the Belgrade area who
were diagnosed during 2006–2009
82 A slightly longer survival time was seen for patients with
hyperlipidemia (TC >5.2 mmol/L, HDL-C <1.6 mmol/L, LDL-C >3.4
mmol/L, and/or TG >1.7 mmol/L) compared to other patients. The
difference was not statistically significant, however.
Reference 13 Patients with ALS enrolled through the Piemonte and
Valle d’Aosta Register for ALS who were diagnosed
during 2007–2011, Italy
638 In univariate analysis, higher levels of TC and LDL-C in men but
lower LDL-C/HDL-C ratios in women were associated with better
survival. Multivariable analysis showed no association of any lipid
measurement (TC, TG, HDL-C, LDL-C, or LDL-C/HDL-C ratio) with
survival.
Reference 18 Patients with ALS recruited in Umeå, Sweden 52 With normalization for diet using the spouses, a positive
correlation was found between survival and TC, VLDL, and LDL-C.
Reference 14 Patients with ALS from 15 European centers who were
enrolled in the clinical trial TRO19622 (Olesoxime)
512 In univariate analysis, TC, LDL-C, and LDL-C/HDL-C ratio were
found to be inversely associated with the risk of death. In analysis
adjusted for age, weight, sex, site of onset, disease duration, and
FVC, none of the lipid measures were found to be associated with
the risk of death.
Reference 19 Patients with sporadic ALS during 2009–2013 in West
China Hospital, China
413 Patients with ALS with higher TG levels had longer survival time
compared to patientswith lower TG levels. Amedian prolonged life
expectancy of 5.8 months was seen for patients with serum TG
levels above the median of 127.5 mg/dL. No difference was seen
for TC, LDL-C, and HDL-C.
Reference 20 Patients with ALS diagnosed during 2000–2013 in
Modena, Italy
275 Higher TG level was associated with a lower risk of death. TC, HDL-
C, and LDL-C did not show an association with risk of death.
Reference 21 Patients with ALS recruited in the ForeFront clinics,
Sydney, Australia
37 A lower TC level was associated with an increased risk of death. No
association was noted for TG. No report for HDL-C and LDL-C.
Reference 22 Patientswith ALS treated at theOnofre LopesUniversity
Hospital in Natal, Brazil, between March 2016 and
December 2016
27 In univariable analysis, TC was inversely correlated with ALSFRS-R
score, whereas LDL-C, HDL-C, and TG levels were positively
associated with the ALSFRS-R score.
Abbreviations: ALS = amyotrophic lateral sclerosis; ALSFR-R = Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised; BMI = body mass index; FVC =
forced vital capacity; HDL-C =high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol; TG = triglycerides; VLDL =
very-low-density lipoprotein.
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had their lipid and apolipoproteinmeasurements precisely at the
time of diagnosis, we fitted all survival models with delayed entry
at the actual time of blood sample collection, calculated as the
time interval between the date of diagnosis and the date of blood
sampling (in months).
We first used the studied biomarkers as continuous variables
and assessed the effect of a 1-SD increase of each biomarker
on the risk of death after ALS diagnosis. We then categorized
these variables according to their quartiles and estimated the
effect of per quartile increase of the studied biomarkers on the
risk of death after ALS diagnosis. We examined the pro-
portional hazard assumption of the Cox model by using sta-
tistics based on Schoenfeld residuals. A slight deviation of the
assumption was noted for site of symptom onset and pro-
gression rate (p < 0.1) but not other variables. After stratifi-
cation of the Cox models by these 2 covariables, the hazard
ratios of other variables were nearly the same as those gen-
erated from models without such stratification. For simplicity
and consistency, we chose to report findings from the original
models without stratifying on these 2 variables. In the main
analysis, we omitted the small number of patients with
missing data in the analysis.15 In a first sensitivity analysis, we
additionally adjusted for the analysis by standard bicarbonate,
and in several other sensitivity analyses, we replaced missing
data with the lowest 25th percentile, the mean, or the highest
25th percentile value of the entire cohort and compared the
results of the sensitivity analyses to those of the main analysis.
In another sensitivity analysis, we restricted the analysis to
patients with lipids and apolipoproteins measured within 1
month after diagnosis to assess the impact of delayed blood
sampling on the results. We also performed a sensitivity
analysis restricting to patients with ALS alone because we
included both patients with ALS and 2 patients with PSMA in
the main analysis. Finally, we performed another sensitivity
analysis using time since symptom onset, instead of time since
diagnosis, as the underlying time scale to assess the potential
influence of different time scales on the study results.
Table 2 Characteristics of patients with ALS
No. of patientsa Mean (SD) or median (IQR)
Sex
Men 52
Women 47
Age at diagnosis, mean (SD), y 99 65.72 (10.09)
Site of symptom onset
Bulbar 38
Nonbulbar 61
Diagnostic delay, median (IQR), mo 99 13.00 (8.60–19.10)
BMI at diagnosis, median (IQR), kg/m2 99 24.38 (22.22–26.67)
ALSFRS-R score at diagnosis, median (IQR) 96 39.00 (33.00–43.50)
Progression rate, median (IQR) 96 0.57 (0.29–1.05)
Biomarkers of lipid metabolism, mean (SD)
TC, mmol/L 94 5.46 (0.95)
LDL-C, mmol/L 92 3.14 (0.88)
HDL-C, mmol/L 94 1.64 (0.51)
LDL-C/HDL-C ratio 91 2.05 (0.77)
TG, mmol/L 94 1.54 (0.98)
Biomarkers of apolipoprotein metabolism, mean (SD)
ApoB, g/L 96 1.08 (0.25)
ApoAI, g/L 96 1.61 (0.28)
ApoB/ApoAI ratio 96 0.69 (0.21)
Abbreviations: ALS = amyotrophic lateral sclerosis; ALSFR-R = Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised; Apo = apolipoprotein; HDL-C =
high-density lipoprotein cholesterol; IQR = Interquartile range; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol; TG = triglycerides.
a Varying number of patients with missing information on some of the characteristics.
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To demonstrate the relative risk of death comparing a high level to
a low level of a specific biomarker, as a secondary analysis, we also
dichotomized the lipids and apolipoproteins at the lowest 25th
percentile for TC, HDL-C, LDL-C, ApoAI, and ApoB and at
the highest 25th percentile for LDL-C/HDL-C ratio, TG, and
ApoB/ApoAI ratio. These cutoffs are generally in agreement with
published guidelines in cardiovascular prevention24,25 and apoli-
poprotein literature.26 Patients with a higher level of a specific
biomarker than the cutoff were classified as having a high level of
the biomarker; patients with a lower level than the cutoff were
classified as having a low level of the biomarker. Kaplan-Meier
survival curves were used to compare median survival time be-
tweenpatients of high and low levels of the studiedbiomarkers, and
log-rank tests were used to assess the between-curve differences.
We also calculated the areas under the receiver operator char-
acteristic curves fromCoxmodels to select a biomarker with the
greatest potential to improve the prediction of ALS prognosis.
From the findings of this analysis, we continued with a survival
prediction and classified patients with ALS according to sex, age
at diagnosis (below or above the mean), site of symptom onset,
diagnostic delay (below or above the median), BMI (below or
above the median), ALSFRS-R score (below or above the
median), progression rate (below or above the median), and
the selected biomarker (dichotomized as high or low).
Statistical Analysis Software (SAS Institute Inc, Cary, NC)
version 9.4 was used for data analysis.
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Regional Ethical Review
Board in Stockholm, Sweden.
Data availability
Researchers can apply for access to data from the present
study for well-defined research questions that are in line with
the overall research agenda for the cohort. Please contact the
corresponding author.
Results
Among the 99 patients, 52 were men and 47 were women
(table 2). The mean age at diagnosis was 65.72 years, and
the median diagnostic delay was 13 months. At the time of
diagnosis, patients had a median BMI of 24.38 kg/m2,
median ALSFRS-R score of 39, and median progression rate
of 0.57. The vast majority (91.92%) of these patients used
riluzole.
Up to October 31, 2018, 54 patients died. The mean survival
time from diagnosis to death was 13.72 months for the de-
ceased patients. After adjustment for sex, age at diagnosis,
site of symptom onset, diagnostic delay, BMI, ALSFRS-R
score, and progression rate, a 1-SD increase of TC, LDL-C,
LDL-C/HDL-C, ApoB, or ApoB/ApoAI ratio was statisti-
cally significantly associated with a lower risk of death after
ALS diagnosis (table 3). Among the 99 patients, 95 pa-
tients had an available measurement of standard bicarbonate.
Further adjustment for standard bicarbonate rendered
largely similar results (data available from Dryad, supple-
mentary table 2, doi.org/10.5061/dryad.df02h35). Sensi-
tivity analyses using the lowest 25th percentile, mean, or
highest 25th percentile values to replace missing values
generated very similar results (data available from Dryad,
supplementary table 3). Restricting the analysis to patients
with lipid and apolipoprotein measurements within 1 month
Table 3 Associations of lipids and apolipoproteins (per 1-SD increase) with risk of mortality after ALS diagnosis with
adjustment for sex, age at diagnosis, site of symptomonset, diagnostic delay, BMI at diagnosis, ALSFRS-R score at
diagnosis, and progression rate
Person-months No. of deceased patients HR (95% CI) p Value
Biomarkers of lipid metabolism
TC 1,355 47 0.60 (0.41–0.89) 0.01
HDL-C 1,355 47 1.12 (0.78–1.61) 0.54
LDL-C 1,316 46 0.64 (0.44–0.92) 0.02
LDL-C/HDL-C ratio 1,295 46 0.65 (0.46–0.92) 0.02
TG 1,355 47 0.88 (0.58–1.34) 0.55
Biomarkers of apolipoprotein metabolism
ApoAI 1,390 50 1.18 (0.85–1.65) 0.33
ApoB 1,390 50 0.62 (0.44–0.88) 0.01
ApoB/ApoAI ratio 1,390 50 0.61 (0.43–0.86) <0.01
Abbreviations: ALS = amyotrophic lateral sclerosis; ALSFR-R = Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised; Apo = apolipoprotein; BMI =
body mass index; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; HR = hazard ratio; LDL-C = low-density lipoprotein cholesterol; TC =
total cholesterol; TG = triglycerides.
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after diagnosis rendered very similar results, although with
slightly limited statistical power (data available from Dryad,
supplementary table 4). Restricting the analysis to patients with
ALS alone similarly led to largely unchanged results (data
available from Dryad, supplementary table 5). Using time since
symptom onset, instead of time since diagnosis, as the un-
derlying time scale provided results similar to those of the main
analyses (data available from Dryad, supplementary table 6).
Finally, using the biomarkers as categorical variables according
to their quartile distributions demonstrated a similar pattern of
results (table 4).
Table 4 Associations of lipids and apolipoproteins (per
quartile increase) with risk of mortality after ALS
diagnosis with adjustment for sex, age at
diagnosis, site of onset, diagnostic delay, BMI at
diagnosis, ALSFRS-R score at diagnosis, and
progression rate
Person-
months
No. of
deceased
patients
HR (95%
CI)
p
Values
Biomarkers of lipid
metabolism
TC, mmol/L
<4.9 247 9 1.00 (Ref)
≥4.9, <5.5 305 11 0.37
(0.14–1.02)
0.05
≥5.5, <6.1 365 14 0.35
(0.12–1.02)
0.05
≥6.1 438 13 0.26
(0.09–0.72)
0.01
HDL-C, mmol/L
<1.3 349 8 1.00 (Ref)
≥1.3, <1.6 297 11 1.38
(0.49–3.88)
0.55
≥1.6, <1.9 375 14 1.61
(0.57–4.53)
0.37
≥1.9 333 14 1.77
(0.59–5.28)
0.31
LDL-C, mmol/L
<2.6 191 10 1.00 (Ref)
≥2.6, <3.1 329 9 0.23
(0.08–0.62)
<0.01
≥3.1, <3.8 378 13 0.37
(0.15–0.92)
0.03
≥3.8 418 14 0.19
(0.07–0.54)
<0.01
LDL-C/HDL-C ratio
<1.6 246 12 1.00 (Ref)
≥1.6, <2.1 295 12 0.77
(0.32–1.85)
0.46
≥2.1, <2.6 349 11 0.60
(0.24–1.52)
0.21
≥2.6 404 11 0.37
(0.14–0.98)
0.02
TG, mmol/L
<0.97 257 9 1.00 (Ref)
≥0.97, <1.30 323 13 0.45
(0.16–1.26)
0.13
≥1.30, <1.90 387 15 0.49
(0.20–1.22)
0.12
≥1.90 388 10 0.48
(0.18–1.25)
0.13
Table 4 Associations of lipids and apolipoproteins (per
quartile increase) with risk of mortality after ALS
diagnosis with adjustment for sex, age at
diagnosis, site of onset, diagnostic delay, BMI at
diagnosis, ALSFRS-R score at diagnosis, and
progression rate (continued)
Person-
months
No. of
deceased
patients
HR (95%
CI)
p
Values
Biomarkers of
apolipoprotein
metabolism
ApoAI, g/L
<1.41 413 12 1.00 (Ref.)
≥1.41, <1.61 252 8 2.42
(0.87–6.69)
0.09
≥1.61, <1.80 344 12 2.06
(0.75–5.68)
0.10
≥1.80 380 18 2.36
(0.93–5.96)
0.07
ApoB, g/L
<0.90 196 11 1.00 (Ref)
≥0.90, <1.09 331 9 0.54
(0.21–1.39)
0.20
≥1.09, <1.29 413 15 0.31
(0.12–0.77)
0.01
≥1.29 450 15 0.21
(0.08–0.56)
<0.01
ApoB/ApoAI ratio
<0.56 261 12 1.00 (Ref)
≥0.56, <0.67 329 12 0.76
(0.32–1.82)
0.58
≥0.67, <0.82 395 11 0.64
(0.27–1.56)
0.31
≥0.82 404 15 0.47
(0.19–1.15)
0.10
Abbreviations: ALS = amyotrophic lateral sclerosis; ALSFR-R = Amyotrophic
Lateral Sclerosis Functional Rating Scale–Revised; Apo = apolipoprotein;
BMI = body mass index; CI = confidence interval; HDL-C = high-density li-
poprotein cholesterol; HR = hazard ratio; LDL-C = low-density lipoprotein
cholesterol; Ref = referent; TC = total cholesterol; TG = triglycerides.
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Patients with high levels of LDL-C, LDL-C/HDL-C ratio,
and ApoB had a statistically significantly longer survival
compared to patients with low levels of these biomarkers
(figure 1). Patients with a high level of LDL-C lived 13.9
months longer than patients with a low level of LDL-C
(median survival 24.4 vs 10.5 months, p < 0.01). Patients
with a high LDL-C/HDL-C ratio lived 6 months longer
compared to patients with a low LDL-C/HDL-C ratio
(median survival 25.5 vs 19.5 months, p = 0.04). Patients
with a high level of ApoB lived 10.5 months longer compared
to patients with a low ApoB level (median survival 21.7 vs
11.2 months, p < 0.01).
Among the Cox models including any of the lipid or apolipo-
protein variables, the model with LDL-C had the largest area
under the curve value at 0.8853, whereas the Coxmodel without
adding any lipid or apolipoprotein variable had an area under the
curve value of 0.8303 (data available fromDryad, supplementary
Figure 1 Kaplan-Meier survival curves
(A) Total cholesterol ≤4.6 vs >4.6mmol/L. Median survival 19.5 vs 21.5months (p = 0.26). (B) High-density lipoprotein cholesterol (HDL-C) ≤1.4 vs >1.4mmol/L.
Median survival 27.9 vs 20.6 months (p = 0.06). (C) Low-density lipoprotein cholesterol (LDL-C) ≤2.6 vs >2.6 mmol/L. Median survival 10.5 vs 24.4 months (p <
0.01). (D) LDL-C/HDL-C ratio <2.5 vs ≥2.5. Median survival 19.5 vs 25.5 months (p = 0.04). (E) Triglycerides <1.8 vs ≥1.8 mmol/L. Median survival 18.4 vs 28.2
months (p = 0.14). (F) Apolipoprotein (Apo) AI ≤1.4 vs >1.4 g/L. Median survival 25.5 vs 18.7months (p = 0.11). (G) ApoB ≤0.9 vs >0.9 g/L. Median survival 11.2 vs
21.7 months (p < 0.01). (H) ApoB/ApoAI ratio <0.82 vs ≥0.82. Median survival 18.8 vs 24.5 months (p = 0.45). Blue lines show patients with a low level of the
biomarker; red lines show patients with a high level of the biomarker.
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table 7, datadryad.org/review?doi=doi:10.5061/dryad.df02h35).
We therefore decided to add LDL-C to the survival prediction
model, in addition to sex, age at diagnosis, site of symptomonset,
diagnostic delay, BMI, ALSFRS-R score, and progression rate.
Figure 2 shows 5 exemplary survival profiles after ALS diagnosis.
Amale patient with a bulbar onset, age at diagnosis ≥66.92 years,
diagnostic delay <12.97 months, BMI <24.38 kg/m2, pro-
gression rate ≥0.57, ALSFRS-R score <39, and level of LDL-C
≤2.6 mmol/L at diagnosis had the shortest predicted median
survival time, whereas a female patient with a nonbulbar onset,
age at diagnosis <66.92 years, diagnostic delay ≥12.97 months,
BMI ≥24.38 kg/m2, progression rate <0.57, ALSFRS-R score
≥39, and level of LDL-C >2.6 mmol/L at diagnosis had the
longest estimated survival time.
Discussion
To the best of our knowledge, no study has previously examined
both lipids and apolipoproteins as potential prognostic indica-
tors for ALS. Using a cohort of 99 patients with ALS who were
representative of all patients with ALS diagnosed during 2015 to
2018 in Stockholm, Sweden, we found that higher levels of TC,
LDL-C, LDL-C/HDL-C ratio, ApoB, and ApoB/ApoAI ratio
were statistically significantly associated with a lower risk of
mortality, after adjustment for all other known prognostic
indicators of ALS.
Several studies using diverse study populations have been
conducted to examine the associations of blood lipids with the
survival of patients with ALS.9–22 While some of the studies
reported that higher lipid levels were indicative of longer
survival after ALS diagnosis,19–21 which is in line with the
present findings, other studies reported a null association
between lipids and ALS survival after multivariable
adjustments.10–12,14,15 The notable discrepancies among
these studies may be attributable to the different study
designs used, the varying timing of lipids measurement, and
the choice of multivariable adjustments. For example, most
studies recruited patients with ALS from neurology clinics
for 2 distinct purposes, namely to investigate the putative
risk factors for ALS using a case-control design9,10,12,18,19,21
or to identify and evaluate potential predictive factors for the
prognosis of ALS using a prospective cohort
design.11,13–15,17,20 In the case-control design settings, it is
relatively common that not only incident cases but also
prevalent cases of ALS were recruited. Because prevalent
cases had to survive until study enrollment, they would have
a longer survival on average compared to incident cases.
Furthermore, the exposure of interest, circulating lipid levels
in this case, might differ between prevalent and incident
cases because lipid levels could be affected by ALS treatment
or the altered lifestyle factors (e.g., diet) after ALS diagnosis.
Using a prospective cohort design with incident cases of ALS
only and measuring lipid levels at the time of diagnosis or
immediately thereafter could largely alleviate such concerns.
An additional concern for both case-control and cohort
studies is the representativeness of the patients enrolled.
While population-based studies are more likely to include
patients of the entire spectrum of disease characteristics,
clinic-based studies are more likely to include patients with
specific characteristics such as younger age at onset or slower
disease progression.27
The choice of multivariable adjustment contributed further to
the conflicting results. Most of the previous studies reported
a significantly improved survival of ALS diagnosis in relation
to a higher level of TG, TC, LDL-C, or LDL-C/HDL-C ratio
in the univariable models (e.g., nonparametric Kaplan-Meier
survival curve).9,11–15,17–21 However, several of these studies
reported that these associations diminished or disappeared
after further controlling for other prognostic indicators of
ALS, and the timing of the measurements of such covariables
is sometimes unclear.12,14,15 Although it is justifiable to adjust
for such covariables measured at the same time as lipids, as we
did in the present study, adjustment of these variables mea-
sured later during the disease process is likely overadjustment.
For example, a few studies found that LDL-C and TC levels
measured at ALS diagnosis were inversely associated with the
speed of decline in ALSFRS-R score and forced vital capacity
after diagnosis.16,22 The prognostic indicators measured after
lipids measurement might therefore be potential mediators
that connect lipids to the survival of ALS and should not be
controlled for in the multivariable-adjusted models. In our
study, adjusting for standard bicarbonate concentrations
measured at the same time as the studied lipids did not change
the results. In addition to the above-mentioned methodologic
Figure 2 Survival prediction curves
Group 1: men, bulbar onset, age at diagnosis ≥66.92 years, diagnostic delay
<12.97 months, body mass index (BMI) <24.38 kg/m2, progression rate
≥0.57, Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised
(ALSFRS-R) score <39, and low-density lipoprotein cholesterol (LDL-C) ≤2.6
mmol/L. Group 2: women, bulbar onset, age at diagnosis ≥66.92 years, di-
agnostic delay <12.97 months, BMI <24.38 kg/m2, progression rate ≥0.57,
ALSFRS-R score <39, and LDL-C >2.6 mmol/L. Group 3: men, bulbar onset,
age at diagnosis ≥66.92 years, diagnostic delay ≥12.97 months, BMI ≥24.38
kg/m2, progression rate ≥0.57, ALSFRS-R score ≥39, and LDL-C >2.6 mmol/L.
Group 4: men, not bulbar onset, age at diagnosis <66.92 years, diagnostic
delay ≥12.97 months, BMI ≥24.38 kg/m2, progression rate <0.57, ALSFRS-R
score ≥39, and LDL-C ≤2.6mmol/L. Group 5:women, not bulbar onset, age at
diagnosis <66.92 years, diagnostic delay ≥12.97 months, BMI ≥24.38 kg/m2,
progression rate <0.57, ALSFRS-R score ≥39, and LDL-C >2.6 mmol/L.
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considerations, true biological variance might also contribute
to the conflicting results noted in the literature. A result
pattern noted in one population, even if valid internally, does
not necessarily extrapolate to an independent population of
different characteristics.
In contrast to the literature on lipids and ALS prognosis, the
role of apolipoproteins on ALS prognosis has rarely been
described. The influence of APOE on the prognosis of ALS
has been studied to some extent, but the findings so far did not
support a strong influence of APOE on disease duration or
overall survival.28 We are the first to report that high levels of
ApoB and ApoB/ApoAI ratio are indicative of longer survival
independently of other known prognostic indicators of ALS.
Together with our recent findings of high levels of ApoB and
ApoB/ApoAI ratio as potential risk factors for ALS,4 more
research is needed to verify the present findings in in-
dependent populations and to understand the underlying
mechanisms.
The strengths of the present study include the use of a study
population that was highly representative of all patients with
ALS diagnosed during the study period in Stockholm, the
enrollment of only incident patients, the measurement of
studied biomarkers at diagnosis or shortly thereafter, the rich
information on clinical characteristics, and the complete
follow-up for all patients included in the analysis. The
comprehensive systemic review of all previously existing
literature on this topic adds another layer to our study. Our
study has also limitations, including the relatively small
sample size, the fact that we did not include all patients
diagnosed during the study period in Stockholm, and the fact
that not all biomarkers were measured precisely at the time
of diagnosis. We studied 99 of the total 217 patients with
ALS who were eligible to participate. However, these
patients did not differ clearly from the remaining 118
patients in terms of demographic and clinical characteristics
(data available from Dryad, supplementary table 1, doi.org/
10.5061/dryad.df02h35), suggesting a satisfactory repre-
sentativeness of study sample. The similar results obtained
from sensitivity analyses argue against a strong influence of
slightly delayed biomarker measurements on the study
results. Another limitation of the study is the lack of genetic
testing for the enrolled patients, which precludes the pos-
sibility of examining the role of lipids for patients with ALS
of known genetic causes.
The underlying mechanisms for the noted associations of
lipids and apolipoproteins with risk of death after ALS di-
agnosis remain unknown. Although we had no information on
forced vital capacity, the similar results obtained after further
adjustment for standard bicarbonate measured at the time of
diagnosis suggest that the associations are not likely con-
founded by respiratory function. We adjusted for BMI mea-
sured at diagnosis in all analyses, but we had no information
on weight change between symptom onset and diagnosis. The
contribution of weight change before diagnosis to the studied
associations therefore remains to be examined. Whether the
noted associations are causal is unknown. For instance, it is
possible that patients with severe and more rapidly pro-
gressing ALS, because of unknown reasons, debut already
lower levels of TC, LDL-C, LDL-C/HDL-C ratio, ApoB, and
ApoB/ApoAI ratio at the time of diagnosis compared to other
patients. The prognostic values of the studied lipids and
apolipoproteins, as shown by the area under the curve values,
are modest compared to other known prognostic indicators
for ALS. However, for patients with specific values of other
prognostic indicators, a different profile of the specific lipids
and apolipoproteins at the time of diagnosis might still in-
dicate differential prognosis. Furthermore, because of the high
statistical correlations between lipids and apolipoproteins, it is
difficult to disentangle the roles of apolipoproteins from the
roles of lipids in the present study. Mechanistic studies are
therefore needed to better understand the potential roles of
apolipoproteins, especially ApoB and ApoB/ApoAI ratio, on
the prognosis of ALS independently of or in interaction with
lipids. For example, the brain is the most lipid-rich organ in
the body, and apolipoproteins play a well-established role in
the transport and metabolism of lipids within the CNS.29
Evidence is also emerging that apolipoproteins fulfill a num-
ber of functions beyond lipid transportation that are critical
for healthy brain function.29 Finally, the underlying reasons
for lipids (e.g., LDL-C) and apolipoproteins (e.g., ApoB) to
be on the one hand potential risk factors for ALS
occurrence4–7 but on the other hand potential protective
factors for survival after ALS diagnosis, as shown in the
present study, need to be studied further. If the present
findings are indeed true, the protective effect on survival could
have contributed partly to the noted positive association be-
tween LDL-C, ApoB, and ALS risk, assuming that patients
with longer survival have higher levels of LDL-C or ApoB, are
more likely to be captured and diagnosed clinically, and are
more likely to be recruited in a research study for ALS (e.g.,
GWAS).
Lipids and apolipoproteins are important prognostic indica-
tors for ALS and should be monitored at the diagnosis of ALS.
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